Commercializing Continuous Processing in Pharma Summit (CCP Summit)

Start Date : January 29, 2019
End Date : January 31, 2019
Time : 8:00 am to4:00 pm

Phone : +16174554188
Email : info@hansonwade.com

Location :
Hyatt Regency Cambridge, 575 Memorial Drive, 02139, Cambridge, United States

Website

Description

Continuous processing is no longer a buzzword in pharma and biotech. Since we started the community in 2017, we have seen a surge of activities and progresses made in the industry globally. Through incremental steps, drug developers are moving through the journey of commercializing continuous manufacturing.


 


Join our growing community of 3rd annual CCP Summit on Jan 29 – 31 in Boston, and stay abreast of project updates and innovative developments.


 


Following two years of success, this 3-day summit will return to offer tailored discussions to help you transform your manufacturing practice. Through case studies and open dialogue, this is the only industry-dedicated platform for you meet and share with like-minded individuals. Get involved today to avoid disappointment.


 


http://continuous-processing-pharma.com/


 


Contact:


info@hansonwade.com


+ 1 617 455 4188


 


Brochure https://go.evvnt.com/302220-0?pid=3506


 


Prices:


Conference + 2 Workshops + Site Visit Earlybird (Book by 11/30/18)USD 4096.0


Conference + 2 Workshops Earlybird (Book by 11/30/18)USD 3597.0


Conference + 1 Workshop + Site Visit Earlybird (Book by 11/30/18)USD 3597.0


Conference + 1 Workshop Earlybird (Book by 11/30/18)USD 3098.0


Conference + 1 Site Visit Earlybird (Book by 11/30/18)USD 3098.0


Conference Only Earlybird (Book by 11/30/18)USD 2599.0


Workshops/Site Visit (each)USD 599.0


 


Speakers: Giustino Di Pretoro (Janssen), David Cho (FDA), Ahmad Almaya (Eli Lilly & Co), Douglas Hausner (C-SOPS), Marcus Fiadeiro (Sanofi)

Registration Info

Register Now

 

Organized by

Organized by LoveEvvnt1

Hanson Wade


Event Categories: Health & Nutrition.




Your Review

You must be logged in to post a comment.